USPTO Examiner AEDER SEAN E - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19059303METHOD FOR IDENTIFYING A SHARED NEOANTIGEN-REACTIVE T CELL RECEPTORFebruary 2025August 2025Allow610NoNo
18991315Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofDecember 2024March 2025Allow310NoNo
18635280Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofApril 2024January 2026Abandon2110NoNo
18628200RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSApril 2024February 2025Allow1110NoNo
18619805ANTI-OX40 ANTAGONISTIC ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASESMarch 2024October 2025Abandon1910NoNo
18592208METHODS OF TREATING TUMORFebruary 2024March 2025Allow1210NoNo
18417162PROSTATE ANTIGEN STANDARDS AND USES THEREOFJanuary 2024August 2025Allow1921NoNo
18408377METHODS OF USING ANTI-SP17 IMMUNOTHERAPEUTICSJanuary 2024November 2024Allow1010YesNo
18396461ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODYDecember 2023January 2025Allow1310NoNo
18542441T CELL RECEPTORS AND FUSION PROTEINS THEREOFDecember 2023April 2024Allow400NoNo
18537973COMPOSITION OF BL-8040December 2023October 2024Allow1020YesNo
18532450SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERSDecember 2023March 2025Allow1621NoNo
18531287DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESDecember 2023August 2024Abandon800NoNo
18529758COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTSDecember 2023February 2025Allow1420NoNo
18529140COMBINATION CANCER THERAPYDecember 2023December 2025Abandon2420YesYes
18516168RESPONSE TO EGFR BLOCKADENovember 2023April 2025Abandon1710NoNo
18495585CIRCULATING TUMOR CELL DIAGNOSTICS FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIESOctober 2023September 2025Abandon2210NoYes
18487818METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHOctober 2023April 2025Abandon1810NoNo
18475552Anti-TIM-3 Antibodies and Use ThereofSeptember 2023February 2025Abandon1710NoNo
18471388HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USESeptember 2023March 2024Allow610YesNo
18469913METHODS AND SYSTEMS FOR SELECTIVE QUANTITATION AND DETECTION OF ALLERGENS INCLUDING GLY M 7September 2023January 2026Abandon2710NoNo
18463209HETERODIMERIC PROTEINSSeptember 2023May 2025Allow2010NoNo
18462648OVARIAN CANCER VACCINESSeptember 2023March 2025Allow1820NoNo
18459857Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofSeptember 2023June 2024Abandon1010NoNo
18456044NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAMEAugust 2023May 2025Allow2130NoNo
18455176IMMUNE-STIMULATING IL-2 FUSION PROTEINSAugust 2023October 2025Abandon2501NoNo
18263430ANTI-NECTIN-4-ANTIBODIES AND USES THEREOFJuly 2023March 2024Allow810NoNo
18270521COMPOSITION OF BL-8040June 2023January 2025Allow1910NoNo
18340774NEUROPILIN-1-PEPTIDE BASED ANTIBODY, HIGHLIGHTING NEW EPITOPE ASSOCIATED TO GLYCOSAMINOGLYCAN-MODIFIED NEUROPILIN-1 AND METHODS OF USE THEREOFJune 2023December 2023Allow500NoNo
18213132HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOFJune 2023February 2025Allow2020NoNo
18211038Methods of Assaying Neoplastic and Neoplasia-Related Cells and Uses ThereofJune 2023January 2025Allow1920NoNo
18325497BIOMARKERS FOR CANCER IMMUNOTHERAPY OUTCOMESMay 2023January 2025Abandon1901NoNo
18200000ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING AZVUDINE AND CHEMOTHERAPEUTIC AGENTMay 2023January 2025Allow2060NoNo
18036610METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHMay 2023May 2025Abandon2520YesNo
18308579DETECTION OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) EXPRESSION ON CIRCULATING TUMOR CELLS (CTC)April 2023September 2025Abandon2920NoYes
18308623HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENSApril 2023March 2025Allow2211NoNo
18134293METHODS OF TREATING COLON CANCER USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPYApril 2023December 2024Abandon2010NoNo
18133822TREATMENT OF CANCER WITH ANTI-GITR AGONIST ANTIBODIESApril 2023September 2024Abandon1710NoNo
18298807THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUSApril 2023October 2024Allow1810NoNo
18126275SYNTHETIC LETHALITY AND THE TREATMENT OF CANCERMarch 2023March 2025Abandon2411NoNo
18186762Immunotherapy Methods for Patients Whose Tumors Carry a High Passenger Gene Mutation BurdenMarch 2023October 2024Allow1910NoNo
18185736IMMUNOMODULATORY ANTIBODIES AND METHODS OF USE THEREOFMarch 2023August 2024Allow1710NoNo
18182297NOVEL HETERODIMERIC PROTEINSMarch 2023January 2026Abandon3421NoYes
18025640APPLICATION OF BACTERIA IN PREPARATION OF SYNERGIST FOR IMMUNE CHECKPOINT INHIBITORMarch 2023February 2026Allow3510NoNo
18175420ANTIBODIES AGAINST TIM3 AND USES THEREOFFebruary 2023January 2025Allow2320NoNo
18173417DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESFebruary 2023January 2024Abandon1100NoNo
18171569METHODS OF DETECTING PROSTATE CANCERFebruary 2023August 2024Allow1811YesNo
18164417CHIMERIC ILT RECEPTOR COMPOSITIONS AND METHODSFebruary 2023February 2025Allow2430YesNo
18163723BIOMARKERS FOR PREDICTING TUMOR RESPONSE TO AND TOXICITY OF IMMUNOTHERAPYFebruary 2023January 2025Allow2310NoNo
18157717PREDICTIVE AND DIAGNOSTIC METHODS FOR PROSTATE CANCERJanuary 2023August 2024Abandon1910NoNo
18151297APTAMER BASED AFFINITY CAPTURE METHODS FOR THE SELECTIVE ENRICHMENT OF HUMAN IMMUNOGLOBULIN FC DOMAINSJanuary 2023April 2025Abandon2720NoNo
18149881MIR-3132 UPREGULATION OF THE TRAIL PATHWAY AND APOPTOTIC ACTIVITY IN CANCER CELLSJanuary 2023April 2024Allow1510YesNo
18088184TUMOR MICROENVIRONMENT-BASED METHODS FOR ASSESSING CAR-T AND OTHER IMMUNOTHERAPIESDecember 2022November 2025Allow3550NoNo
18082368NANOPARTICLES AND DISTINCT EXOSOME SUBSETS FOR DETECTION AND TREATMENT OF CANCERDecember 2022November 2024Allow2321NoNo
18078088WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATESDecember 2022December 2024Abandon2410NoNo
18062419DETECTING NEOPLASMDecember 2022March 2024Allow1510NoNo
18007859HIV-1 ANTIBODIESDecember 2022November 2025Allow3510YesNo
18057627Novel Method For Producing Low Viscous And Highly Concentrated Biopharmaceutical Drug Products In Liquid FormulationNovember 2022March 2025Abandon2720NoNo
17998795SMC1A ANTIBODIES AND USES THEREOFNovember 2022January 2026Allow3810NoNo
18054597ONCOLYTIC VIRUS VACCINE AND DRUG FOR TREATING TUMORS BY COMBINING ONCOLYTIC VIRUS VACCINE WITH IMMUNE CELLSNovember 2022October 2025Allow3510NoNo
18054307METHODS FOR THE DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMANovember 2022June 2025Abandon3140NoNo
17924542COMPOSITION FOR THE TREATMENT AND/OR PREVENTION OF MARINE MOLLUSC VIRAL INFECTIONNovember 2022January 2026Abandon3910NoNo
18047285VIRUS COMPOSITIONOctober 2022August 2024Allow2211NoNo
17968386N6-Methyladenosine Regulators in Uterine FibroidsOctober 2022March 2026Allow4121NoNo
18047216METHODS OF TREATING TUMOROctober 2022October 2023Allow1210YesNo
18046565NON-INVASIVE TEST TO PREDICT RESPONSE TO THERAPY IN COLORECTAL CANCER PATIENTSOctober 2022October 2024Abandon2420NoNo
17932259CHIMERIC ANTIGEN RECEPTOR AND METHODS OF USE THEREOFSeptember 2022August 2024Allow2320NoNo
17940883PLASMA AUTOANTIBODY BIOMARKERS FOR BASAL LIKE BREAST CANCERSeptember 2022May 2024Allow2012NoNo
17904098USE OF ANTI-PD-1 ANTIBODY IN TREATING NEUROENDOCRINE TUMORSAugust 2022January 2026Abandon4110NoNo
17760202METHODS FOR DISCONTINUING A TREATMENT WITH A TYROSINE KINASE INHIBITOR (TKI)August 2022January 2026Abandon4110NoNo
17817886IMMUNE-STIMULATING IL-2 FUSION PROTEINSAugust 2022May 2023Allow1020YesNo
17817862DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESAugust 2022May 2023Abandon900NoNo
17797662ZIKA VIRUS IMMUNOGENIC COMPOSITIONSAugust 2022September 2025Allow3710NoNo
17796788FUSION ANTIBODY FOR PRESENTING ANTIGEN-DERIVED T CELL ANTIGEN EPITOPE OR PEPTIDE CONTAINING SAME ON CELL SURFACE, AND COMPOSITION COMPRISING SAMEAugust 2022October 2025Allow3920NoNo
17793503RECOMBINANT FULLY HUMAN ANTI-TIGIT MONOCLONAL ANTIBODY FORMULATION, METHOD FOR PREPARING SAME AND USE THEREOFJuly 2022January 2026Abandon4210NoNo
17792250METHODS FOR THE TREATMENT OF CANCERJuly 2022December 2025Abandon4110NoNo
17789888USE OF THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH TUMORS OF EPITHELIAL ORIGINJune 2022March 2026Allow4540NoNo
17848694RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSJune 2022November 2023Allow1710YesNo
17846966BIOMARKERS AND USES THEREOF FOR SELECTING IMMUNOTHERAPY INTERVENTIONJune 2022April 2024Abandon2111YesNo
17843852METHODS OF TREATING FIBROBLAST GROWTH FACTOR 19-MEDIATED CANCERS AND TUMORSJune 2022June 2025Abandon3610NoNo
17785484METHOD FOR PREDICTING SENSITIVITY OF CANCER CELL TO GPX4 INHIBITORJune 2022September 2025Allow3910NoNo
17806218CD3/CD38 T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS AND METHODS OF THEIR PRODUCTIONJune 2022February 2024Allow2020NoNo
17783439METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING A SAGE1-RELATED CONDITIONJune 2022November 2025Allow4221NoNo
17805336CANCER TREATMENTJune 2022July 2024Abandon2520NoNo
17826477BIOMARKERS PREDICTIVE OF ANTI-IMMUNE CHECKPOINT RESPONSEMay 2022April 2025Allow3531NoNo
17752519WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATESMay 2022September 2022Allow310NoNo
17778446INHIBITORS OF ADRENOMEDULLIN FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA BY ERADICATING LEUKEMIC STEM CELLSMay 2022December 2025Abandon4210NoNo
17744262METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTINMay 2022February 2025Allow3340NoNo
17739308HUMANIZED, MOUSE OR CHIMERIC ANTI-CD47 MONOCLONAL ANTIBODIESMay 2022April 2024Allow2410YesNo
17739317TCR, POLYPEPTIDE, EXPRESSION VECTOR, HOST CELL, PHARMACEUTICAL COMPOSITION AND METHOD FOR OBTAINING TCRMay 2022November 2024Allow3131NoNo
17736475HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CD38May 2022June 2024Allow2511NoNo
17722051NON-CODING RNA FOR DETECTION OF CANCERApril 2022November 2023Abandon1930YesNo
17769245METHODS FOR DETECTING AND INHIBITING BRAIN METASTASISApril 2022December 2025Allow4420YesNo
17715092DETECTION OF DESMOGLEIN-2 IN CANCERS OF EPITHELIAL ORIGINApril 2022March 2026Allow4720NoNo
17762703BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTIONMarch 2022January 2026Allow4621NoNo
17762530BIOMARKERS FOR ANTI-TIGIT ANTIBODY TREATMENTMarch 2022November 2025Abandon4401NoNo
17760869Methods and Kit for Analyzing Responsiveness of Patients to CD19 ImmunotherapyMarch 2022September 2025Allow4220NoNo
17654801Method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseasesMarch 2022September 2023Allow1810NoNo
17690634METHODS FOR THE TREATMENT OF CANCERMarch 2022June 2024Abandon2720NoNo
17639783ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODYMarch 2022September 2023Allow1900NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AEDER, SEAN E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
31
Examiner Affirmed
17
(54.8%)
Examiner Reversed
14
(45.2%)
Reversal Percentile
67.8%
Higher than average

What This Means

With a 45.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
219
Allowed After Appeal Filing
40
(18.3%)
Not Allowed After Appeal Filing
179
(81.7%)
Filing Benefit Percentile
22.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner AEDER, SEAN E - Prosecution Strategy Guide

Executive Summary

Examiner AEDER, SEAN E works in Art Unit 1642 and has examined 1,644 patent applications in our dataset. With an allowance rate of 51.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner AEDER, SEAN E's allowance rate of 51.0% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by AEDER, SEAN E receive 2.39 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by AEDER, SEAN E is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +28.0% benefit to allowance rate for applications examined by AEDER, SEAN E. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.9% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 41.8% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 58.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 49% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 73.9% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 76.8% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.5% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 63% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.